EPIX Pharmaceuticals

EPIX Pharmaceuticals is a biopharmaceutical company that discovers and develops therapeutic drugs for the treatment of central nervous system and pulmonary diseases through the use of its proprietary silicon drug discovery technology. Its developed therapeutic product PRX-08066, a small molecule inhibitor, has completed Phase II clinical trials for the treatment of pulmonary hypertension and pulmonary arterial hypertension associated with chronic obstructive pulmonary disease (COPD); and PRX-07034, which has completed Phase I studies for the treatment of cognitive impairment associated with schizophrenia. The company also offers Vasovist, an injectable intravascular contrast agent that provides enhanced vascular imaging using magnetic resonance angiography. It collaborates with SmithKline Beecham Corporation, Amgen Inc., and Cystic Fibrosis Foundation Therapeutics.